SELECTIVE ELIMINATION OF EROSIVE CELLS
The current invention relates to the treatment of diseases characterized by cartilage destruction and/or bone erosion. In particular the present invention relates to the treatment of osteoarthritis, osteoporosis, psoriatic arthritis or rheumatic arthritis with an anti-NKG2A antibody.
Saved in:
Main Authors | , |
---|---|
Format | Patent |
Language | English |
Published |
28.12.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Be the first to leave a comment!